Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Cantor Fitzgerald Reaffirms Their Buy Rating on ProQR (PRQR)

Tipranks - Tipranks - Fri Jul 18, 2025

In a report released today, Steven Seedhouse from Cantor Fitzgerald reiterated a Buy rating on ProQR, with a price target of $8.00. The company’s shares opened today at $2.35.

Elevate Your Investing Strategy:

Seedhouse covers the Healthcare sector, focusing on stocks such as ProQR, Wave Life Sciences, and Apellis Pharmaceuticals. According to TipRanks, Seedhouse has an average return of 9.0% and a 42.82% success rate on recommended stocks.

Currently, the analyst consensus on ProQR is a Strong Buy with an average price target of $9.57, implying a 307.23% upside from current levels. In a report released on July 11, Evercore ISI also maintained a Buy rating on the stock with a $5.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $4.62 and a one-year low of $1.07. Currently, ProQR has an average volume of 419.8K.

Read More on PRQR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).